جستجوی استاد راهنمای دانشگاهی

Andy Howdenمشاهده پروفایل

مدرس

• Quantitative Proteomics
• Protein Biochemistry
• Immune Cell Signaling
• +۵ مورد دیگر

Dr. Andy Howden serves as a Principal Investigator and Lecturer (Teaching and Research) in the Cell Signalling and Immunology group within the School of Life Sciences at the University of Dundee. With an h-index of 23 and 2199 citations, his research program is well-established in the fields of quantitative proteomics and immune cell biology. Dr. Howden's research focuses on using quantitative proteomics and protein biochemistry to provide molecular understanding of how immune cells sense and respond to their environment. He has a specific interest in T and B lymphocytes and their links to neurodegenerative diseases. His recent work investigates kinase signaling pathways, particularly Leucine-rich Repeat Kinase 2 (LRRK2), and how these relate to conditions like Parkinson's and Crohn's disease, as well as immune cell metabolism and autophagy regulation. His recent publications (2024-2025) demonstrate strong output in high-impact journals including Nature Communications, Nature Immunology, and EMBO Reports, with research spanning immunology, proteomics, and neurodegenerative disease mechanisms. These works reveal consistent themes in immune cell signaling, metabolic regulation, and the molecular connections between inflammation and neurological conditions. Active investigator on 'Immune cell profiling and quality control position' project (2025-2026) Previously involved in Rapid Research in Covid-19 Programme (2020-2021) Regularly serves as grant reviewer for MRC projects As an educator, Dr. Howden manages the Level 3 Cell Signalling (BS32006) and Level 4 Advanced Cell Signalling (BS42013) modules, and lectures in Level 3 Immunology (BS32009). He is actively involved in the Dundee Research Interest Group and has organized outreach events including the Open Doors Day Event. His ORCID profile (0000-0002-4332-9469) documents his extensive research contributions across immunology and cell signaling disciplines.

• Cardiovascular Science
• Cardiac Fibrosis
• Primary Cilia
• +۳ مورد دیگر

Elisa Villalobos is a Postdoctoral Research Fellow at the Centre for Cardiovascular Science, University of Edinburgh, with prior research experience at UT Southwestern Medical Center and the University of Chile. Her work bridges cardiovascular biology and metabolic disease research, focusing on molecular mechanisms of cardiac fibrosis and inflammation in obesity. Her research interests center on primary cilia as cardiac mechanosensors and calcium signaling pathways in adipose tissue. Key investigations include polycystin-dependent regulation of fibroblast activity in heart failure, cGAS-mediated inflammatory responses in myocardial injury, and calcium sensing receptor modulation of adipocyte inflammation. This work reveals fundamental connections between cellular structures, signaling pathways, and disease pathogenesis. Analysis of her 14 publications shows consistent progression from metabolic inflammation research (2011-2014) toward cardiovascular mechanisms (2015-2019), with increasing emphasis on translational aspects of heart failure. Her recent work in Nature and Circulation demonstrates significant contributions to understanding nitrosative stress in diastolic dysfunction and primary cilia in cardiac fibrosis. Dr. Villalobos actively contributes to the academic community through editorial roles at Frontiers in Physiology and peer review for major cardiology journals. While not independently supervising students, she mentors junior researchers within collaborative projects funded by British Heart Foundation grants at the Centre for Cardiovascular Science, which provides state-of-the-art facilities for cardiovascular research including advanced imaging and molecular phenotyping platforms.

Mamta Chawla Sarkarمشاهده پروفایل

استاد

• Virology
• Molecular Epidemiology
• Host-Pathogen Interactions
• +۵ مورد دیگر

Dr. Mamta Chawla Sarkar serves as Scientist G at the National Institute of Cholera and Enteric Diseases (NICED), Kolkata, leading virology research under the Indian Council of Medical Research. Her work bridges fundamental molecular studies and public health implementation through NICED's WHO Collaborating Centre designation and national surveillance networks for rotavirus and influenza. Her research expertise spans: Molecular epidemiology of enteric/respiratory viruses Host-pathogen interactomics using proteomics and RNA-seq Development of low-cost diagnostic assays Host-targeted antiviral therapeutics Recent publications reveal a strategic pivot toward lncRNA-mediated mechanisms in viral pathogenesis, with 8 of 15 recent papers exploring non-coding RNA roles in rotavirus and SARS-CoV-2 infection. The work demonstrates sophisticated integration of clinical samples from NICED's hospital collaborations with advanced OMICS platforms to identify druggable host pathways. Her scientific recognition includes: Fellowship of Indian National Science Academy (2020) DBT National Women Bioscientist Award (2013) ICMR Kanishka Oration Award (2017) Fellowships from NASI and West Bengal Academy of Science Mentorship and funding reflect sustained excellence: 21 PhD students trained (15 awarded), continuous project funding since 2006 including ICMR's Centre for Product Development (2019-2024) and DST-SERB grants. During pandemics, her lab provided critical diagnostic support while advancing mechanistic studies - exemplifying translational research impact. The laboratory operates within NICED's BSL-3 facility as part of the Virology Division, coordinating eastern India's viral disease surveillance through 12+ network laboratories. Current work focuses on lncRNA-mediated ferroptosis in rotavirus infection and HDAC6 modulation in SARS-CoV-2 replication.

Moua Yangمشاهده پروفایل

استادیار

• Thrombosis Mechanisms
• Redox Biology
• Oxidative Cysteine Modification
• +۵ مورد دیگر

Moua Yang, Ph.D. is an Academic Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine and an Assistant Member at the Bloodworks Northwest Research Institute in Seattle, Washington. His research focuses on redox mechanisms in thrombosis, with particular emphasis on oxidative cysteine modifications and thiol isomerases in clot formation. Dr. Yang received his undergraduate degree from the University of Wisconsin-Stevens Point, followed by a Ph.D. from the Medical College of Wisconsin. He completed postdoctoral training at the Medical College of Wisconsin and later at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Yang's primary research investigates the redox mechanisms that promote thrombosis, with specific focus on oxidative cysteine modification and its role in thrombotic machinery. His laboratory employs chemical biology, protein biochemistry, and real-time intravital imaging to unravel these mechanisms. He also studies thiol isomerases - enzymes that function to make and break disulfides during protein folding - which escape into the bloodstream and play critical roles in clot formation. His research explores how these enzymes promote thrombus formation in oxidative stress conditions, with specific areas of study including mechanisms of vaso-occlusion by thiol isomerases and natural compounds as anti-thrombotics. Analysis of Dr. Yang's recent publications reveals a strong focus on redox biology in thrombosis, with particular emphasis on cysteine oxidation, thiol isomerases, and CD36 signaling pathways. His work spans basic mechanisms of thrombosis, translational applications for antithrombotic therapy, and even extends to research on high-altitude physiology and diversity in STEMM fields. A notable trend is his exploration of natural compounds, particularly polyphenols, as potential antithrombotic agents targeting redox-sensitive pathways. Dr. Yang leads a research laboratory at Bloodworks Northwest Research Institute, where he mentors research technologists including Osamede C. Owegie and John K. Ryan. His laboratory investigates the molecular mechanisms of thrombosis with applications for developing novel antithrombotic therapies.

• Neurodegenerative diseases
• Alzheimer's disease
• Microglia
• +۵ مورد دیگر

Prof. Dr. Jonas Neher serves as a Group Leader at the German Center for Neurodegenerative Diseases (DZNE) in Munich, where he leads research focused on the role of microglia and immune responses in neurodegenerative diseases, particularly Alzheimer's disease. His laboratory investigates how peripheral inflammation affects brain pathology through mechanisms like innate immune memory and epigenetic reprogramming. Dr. Neher's research program centers on understanding how microglia contribute to Alzheimer's pathology, particularly amyloidosis and neuronal damage. He has demonstrated that microglia are capable of 'remembering' inflammatory insults through epigenetic reprogramming, creating long-term adaptations that significantly affect brain disease progression. His work has established innate immune memory as a previously unrecognized non-genetic risk factor for neurodegenerative diseases. Additionally, he studies vascular dysfunction in Alzheimer's disease, with a particular focus on medin amyloid, which is now recognized as a common factor in age-related arterial stiffening and a potential therapeutic target for millions affected by cognitive decline. Analysis of Dr. Neher's publication record reveals a strong trajectory from fundamental immunological mechanisms to translational applications. His recent work (2022-2024) shows increasing focus on medin amyloid's role in vascular pathology, with high-impact publications in Nature and Nature Aging. His laboratory has developed specialized single-cell profiling techniques that combine transcriptomic and epigenetic analyses to better understand cellular heterogeneity in neurodegenerative conditions. This methodological innovation enables more precise characterization of microglial subtypes and their responses to inflammatory stimuli. Dr. Neher leads an active research group investigating how peripheral inflammatory stimuli affect the brain's immune response and contribute to neurodegenerative disease pathology. His laboratory has developed specialized methods for profiling microglia and other brain cells at the single-cell level, combining transcriptomic and epigenetic analyses to better understand cellular heterogeneity in health and disease. His research bridges basic science with potential clinical applications, particularly in developing new therapeutic strategies targeting both immune and vascular components of Alzheimer's disease.

• Systems Immunology
• Genomics
• Artificial Intelligence
• +۴ مورد دیگر

Prof. Dr. Joachim L. Schultze is Director of Systems Medicine at the German Center for Neurodegenerative Diseases (DZNE) and leads the Genomics & Immunoregulation group at the University of Bonn's LIMES Institute. His research integrates immunology, neurobiology, genomics, and artificial intelligence, with a focus on single-cell technologies and systems medicine approaches. Key research areas include: Swarm Learning : Development of decentralized AI frameworks for medical research NEUROCOV : Investigation of neurological complications in COVID-19 PRECISE Platform : Single-cell genomics and epigenomics technology development Systems immunology approaches for chronic inflammatory diseases Myeloid cell biology and trained immunity mechanisms His recent publications (2019-2022) demonstrate strong focus on: COVID-19 immunopathology and myeloid cell dysregulation Neuroimmunology and neurodegenerative disorders AI/blockchain applications in healthcare Single-cell transcriptomics in inflammation Metabolic regulation of immune cells Prof. Schultze coordinates multiple international consortia including the DFG-funded NGS Competence Network and Immunosensation2 Cluster of Excellence. His laboratory combines experimental genomics with computational biology at the PRECISE joint platform between DZNE and University of Bonn.

Marion Emilie Genevieve Brunckمشاهده پروفایل

پژوهشگر

• Immunology
• Systems Biology
• Biotechnology
• +۴ مورد دیگر

Marion Emilie Genevieve Brunck serves as a Researcher at Tecnológico de Monterrey's School of Engineering within the Department of Biotechnology, where she leads the Biotechnology Center-FEMSA. Her laboratory focuses on immune cell function mechanisms with applications in immunomodulation and therapeutic development. Bachelor of Science, The University of Queensland Brisbane Doctor of Philosophy in Immunology and Systems Biology, The University of Queensland Brisbane (2015) Dr. Brunck's research integrates immunology, systems biology, and biotechnology to investigate endogenous/exogenous triggers modifying immune cell phenotypes. Her work spans neutrophil biology, obesity-related immunomodulation, maternal-fetal immunity, and therapeutic cell platform development. The laboratory employs OMICS methodologies, flow cytometry (including BD FACSCelesta), and synthetic biology approaches to study immune cell progenitors and their applications. Her 15 most recent publications demonstrate strong focus on immunometabolism, maternal-child immunology, and translational immunotherapies. Key trends include investigating leukocyte dynamics in breastmilk, macrophage metabolism in cardiometabolic disease, and neutrophil engineering for therapeutic applications. Research spans basic immunology through clinical applications with emphasis on Latin American health contexts. Competitive Research Scholarship from Stem Cells Australia Mexican Researcher Certification - Level 2 Dr. Brunck actively mentors through TEC's School of Engineering postgraduate society (Rho Factor) and SACBE STEM, promoting women in science. She supervises 4 MSc and 2 PhD students in the Brunck Lab, which maintains comprehensive immunology research infrastructure. Her collaborative work includes partnerships with the Mexican Society of Immunology and Mexican Society for Biotechnology and Bioengineering. The Brunck Lab operates within the Biotechnology Center-FEMSA at Campus Monterrey, equipped with BD FACSCelesta flow cytometer, biosafety hoods, incubators, and molecular biology equipment. Her team investigates immune cell phenotypic modifications for therapeutic applications while contributing to public science education through the American Association of Blood Banks and STEM outreach initiatives.

Jan G. Hengstlerمشاهده پروفایل

استاد

• Toxicology
• Pharmacology
• Molecular Biology
• +۵ مورد دیگر

Prof. Dr. Jan G. Hengstler serves as Head of the Department of Systems Toxicology at the Leibniz Research Centre for Working Environment and Human Factors in Dortmund, Germany. With a distinguished career spanning over three decades, he previously held positions as Professor of Molecular Pharmacology and Toxicology at the University of Leipzig (2003-2007) and conducted research at the Institute of Toxicology, University of Mainz (1990-2003). Dr. Hengstler completed his medical studies at the University of Mainz (1984-1990), obtained his medical license in 1992, and completed his MD thesis on DNA damage in 1991. He achieved his habilitation in Pharmacology and Toxicology in 1998 and specialized as a physician in Pharmacology and Toxicology in 1997. His research focuses on the molecular mechanisms of liver disease, particularly cholestatic liver injury, bile acid metabolism, and the gut-liver axis. His work integrates toxicology, pharmacology, and molecular biology to investigate how environmental and pharmaceutical compounds affect liver function. Recent studies examine bile acid signaling, gut microbiome interactions, and mechanisms of liver fibrosis and carcinogenesis. His research employs advanced methodologies including iPSC-derived hepatocyte models, in vivo mouse models, and systems toxicology approaches. Analysis of his 15 most recent publications reveals a strong emphasis on translational research with significant clinical implications, particularly in cholestatic liver diseases, drug-induced liver injury, and cancer mechanisms. His work frequently appears in high-impact journals including Hepatology, Nature Metabolism, and Journal of Hepatology. Dr. Hengstler leads an active research group within the Toxicology department at the Leibniz Research Centre, collaborating with multiple international institutions. His laboratory maintains strong connections with clinical researchers and utilizes both experimental and computational approaches to investigate liver pathophysiology.

• Toxicology
• Hepatology
• Drug Metabolism
• +۵ مورد دیگر

Daniela González Leiva is a Scientific Associate in the Department of Intravital Toxicology at the Technical University of Dortmund, where she conducts research on liver toxicology, drug metabolism, and bile acid pathways. Her work primarily focuses on understanding the mechanisms of drug-induced liver injury, species differences in toxin metabolism, and the role of various proteins in liver disease progression. Dr. González Leiva's research interests span multiple areas of toxicology with a particular emphasis on hepatotoxicity , bile acid metabolism , and species differences in drug metabolism . Her work combines intravital imaging techniques with molecular and biochemical analyses to investigate how toxins and drugs affect liver and kidney function. She has made significant contributions to understanding acetaminophen toxicity , ochratoxin A metabolism , and the role of WISP1 protein in liver fibrosis and cancer progression. Analysis of Dr. González Leiva's recent publications reveals a consistent focus on liver toxicology with particular attention to bile acid metabolism, drug-induced liver injury, and species differences in toxin processing. Her work frequently employs mouse and rat models to study hepatotoxicity , nephrotoxicity , and metabolic disorders . A notable trend is her investigation of WISP1 protein in liver fibrosis and cancer, as well as her research on how hypoalbuminemia affects toxin distribution and the mechanisms of blood-bile barrier disruption. As a member of the Intravital Toxicology team led by Prof. Dr. Jan G. Hengstler, Dr. González Leiva collaborates with researchers across multiple disciplines including hepatology, nephrology, and analytical chemistry. The team utilizes advanced imaging techniques and molecular analyses to study real-time physiological processes in living organisms, providing insights into the mechanisms of toxicity and disease progression.

Andrew P. Laneمشاهده پروفایل

استاد

• Nasal polyps
• Chronic sinusitis
• Endoscopic orbital surgery
• +۷ مورد دیگر

Dr. Andrew P. Lane is a Professor of Otolaryngology-Head and Neck Surgery at Johns Hopkins University School of Medicine and serves as the Director of the Johns Hopkins Sinus Center. With over two decades of experience since joining Johns Hopkins in 2001, he is recognized as the longest practicing sinus specialist with advanced fellowship training in the Baltimore/Washington region. Dr. Lane's research focuses on understanding the molecular mechanisms underlying chronic rhinosinusitis, particularly the pathogenesis of nasal polyps and inflammation of the olfactory epithelium. His laboratory employs diverse techniques in molecular biology, immunology, and physiology to study epithelial cell innate immunity, olfactory loss, and response to viral infection. Key research areas include: Nasal polyps and chronic sinusitis pathogenesis Endoscopic orbital and skull base surgery Innate immunity of the nose and sinuses Inverted papilloma Olfactory loss due to chronic sinusitis Underlying mechanisms of chronic inflammation Through his extensive publication record of over 140 articles, Dr. Lane has established himself as a leader in rhinology research, with recent work focusing on the intersection of inflammation, olfactory function, and viral infections including SARS-CoV-2 variants. His laboratory creates and employs transgenic mouse models of chronic nasal/sinus inflammation and collaborates with the School of Public Health to explore mechanisms of anti-viral immunity. Dr. Lane has received numerous prestigious awards for his research, including the Earleen Elkins Research Award, GlaxoSmithKline research award, and Passano Foundation Clinician Scientist Award. He serves as Editor-in-Chief of Current Otorhinolaryngology Reports and holds editorial positions with several leading journals in the field. As a clinician, Dr. Lane maintains a busy practice performing the full range of endoscopic sinus procedures, including transnasal skull base and orbital surgeries. He is dedicated to providing cutting-edge care to his patients while developing new therapies for chronic rhinosinusitis through his clinical and basic science research.